FDA Drug Advisory Committee Pediatric Ethics Subcommittee Gonadotropin Releasing Hormone Agonist Test in Disorders of Puberty CHARGE TO COMMITTEE Norman.

Slides:



Advertisements
Similar presentations
Human Subjects Research at the University of Michigan
Advertisements

Children as Human Research Subjects Subpart D A Presentation for IRB Members.
Marian University is sponsored by the Sisters of St. Francis, Oldenburg. Human Subjects Research and the Marian University Institutional Review Board (IRB)
University Research Ethics Committee Workshop on procedure and data protection issues 30th May 2008.
Human Subjects Protections, Concepts, and Procedures Office of Research and Sponsored Programs Tom Lombardo, Ph.D., Director, Research Integrity & Compliance.
Protecting the Privacy of Family Members in Survey and Pedigree Research Jeffrey R. Botkin, MD, MPH University of Utah.
Ethical Considerations when Developing Human Research Protocols A discipline “born in scandal and reared in protectionism” Carol Levine, 1988.
Workshop on Cell and Gene Therapy Clinical Trials in Pediatric Populations, Nov. 2, 2010 The Scientific and Ethical Path Forward in Pediatric Product Development.
Jeopardy Rules Game show host will divide the room into two teams When you know the answer, raise your hand and wait to be called on Your answer must.
SUBPART D PRESENTATION Inaugural meeting of the Pediatric Ethics Subcommittee (PES) of the Pediatric Advisory Committee (PAC); part of the inaugural meeting.
Pediatric Ethics Subcommittee of Pediatric Advisory Committee, September 10, 2004 Analysis of Research Protocols Involving Children: Combining Subparts.
Use of Children as Research Subjects What information should be provided for an FP7 ethical review?
Slide 1 How to Review: Research Involving Children & Adolescents in 5 Steps Susan Kornetsky, MPH, CIP Director, Clinical Research Compliance Children’s.
Ethical Guidelines for Research with Human Participants
8 Criteria for IRB Approval of Research 45 CFR (a)
Introduction. Research with Minors A Harvard Longwood QIP Education Session Matthew Stafford Assistant Director, Clinical Research Compliance.
Determinations of Research, Human Subjects Research, Exemptions, and Expedited Review Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst, Program for.
Is this Research? Exempt? Expedited?
Precursor Preference in Surfactant Synthesis of Newborns Sarah Frankel, PhD Human Studies Committee Washington University School of Medicine.
The Minimal Risk Standard Revealed Leah Belsky Ezekiel J. Emanuel Kimberly Thompson David Wendler.
April 2011 Conducting Research at SPC Approval Process and Procedures Center of Excellence for Teaching and Learning.
Overview of Research Oversight: U.S. Perspective Leslie K. Ball, M.D., F.A.A.P. Office for Human Research Protections Department of Health and Human Services.
Expedited Procedures Bob Craig June Expedited problems Usually individual investigators (rather than trained coordinators) Individuals not “ active.
1 Ethical Issues Concerning the Protection of Children in Biomedical Research in Japan Takahiro NISHIMURA (PhD, Osaka University, JAPAN)
Risk by Richard R. Riker MD Vice-Chair, IRB Maine Medical Center.
Human Research Protection Program 101 July 19-20, 2007 Milwaukee, WI.
Committee on Human Research Processes Clinical Translational Research Fellowship Program Curriculum Core.
West Virginia University Office of Research Integrity & Compliance Human Research Protections Program.
Teaching Research Methods (Classroom Protocols) Boston University Charles River Campus Boston University Medical Center Mary A. Banks BS, BSN IRB Director.
Research With Children The Ethical Imperative: Don’t Underprotect or Overprotect Ernest D. Prentice, Ph.D. University Of Nebraska Medical Center Revised.
1 Protection of Vulnerable Subjects in Research Melody Lin, Ph.D. December 2012.
Status of SACHRP Recommendations July 2003-October 2008 Meeting of the Secretary’s Advisory Committee on Human Research Protections October 27, 2008 Michael.
Challenges of 21st Century Clinical Research from an Independent IRB’s View Chesapeake Research Review, Inc. Paul Goebel, CIP Vice President Matthew Whalen,
Case Studies: Puzzles in Human Research Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst, Program for Research Integrity Development and Education.
APPROVAL CRITERIA AN IRB INFOSHORT MAY CFR CRITERIA FOR IRB APPROVAL OF RESEARCH In order for an IRB to approve a research study, all.
WELCOME to the TULANE UNIVERSITY HUMAN RESEARCH PROTECTION OFFICE WORKSHOP for SOCIAL/BEHAVIORAL RESEARCH (March 2, 2010) Tulane University HRPO Uptown.
Regulatory requirements: children, assent, and consent waivers and waiver of documentation Bob Craig, 2007.
FDA Drug Advisory Committee Pediatric Ethics Subcommittee Gonadotropin Releasing Hormone Agonist Test in Disorders of Puberty SUMMARY OF PUBLIC COMMENTS.
Pediatric Research Ethics and the Research Subject Advocate Tomas Jose Silber, MD, MASS RSA and Director, Office of Ethics, CNMC Professor of Pediatrics,
Human Specimen Repositories Requirements of 21 CFR Parts 50 & 56 PRIM & R May 5, 2004 Sally A. Hojvat, Ph.D. Director of Microbiology Devices Office of.
Exempt Unless otherwise required by Department or Agency heads, research activities in which the only involvement of human subjects will be in one or more.
Legal Responsibilities for Studies Conducted or Supported by HHS Michael A. Carome, M.D. Associate Director for Regulatory Affairs Office for Human Research.
Human Research Protection Program 101 March 20, 2007 Cincinnati, OH.
0 Ethics Lecture Research. ACADEMY OF OPHTHALMOLOGY Disclosures  The speaker has no financial interest in the subject matter of this.
IRB Presentation to the Pediatric Ethics Subcommittee of the FDA regarding “Gonadotropin Releasing Hormone (GnRH) Agonist Test in Disorders of Puberty”
Ethical issues with children and families in research
Institutional Review Board
Brief Overview of IRB and Human Subject Protections Issues at the University of Richmond Dr. R. Kirk Jonas Chair, University of Richmond Institutional.
Children in Research: They’re Not Just Small Adults
Risk Determinations and Research with Children
Brief Overview of IRB and Human Subject Protections Issues at the University of Richmond Dr. R. Kirk Jonas Chair, University of Richmond Institutional.
University of Central Florida Office of Research & Commercialization
What is a Data and Safety Monitoring Plan and how do I get one?
Anna C. Mastroianni, JD, MPH
Criteria for Approval Is an IND Required? Devices
Protection of Human Subjects In Research
University of Central Florida Office of Research & Commercialization
Lana Gevorkyan Corporate Director Human Research Protection Program
IRB Educational Session - IRB Regulations and Types of Review
USC Institutional Review Boards
Ethics and Regulation of Research with Children
Children as Subjects – Important Ethical and Logistical Considerations
Today’s Agenda: Ethics Cont. HW: Read & 1.6 (1.5 optional…)
Exploring 45 CFR , Criteria for IRB Approval of Research
IRB Educational Session - IRB Regulations on Expedited Review
Determining the Appropriate IRB Application for Your Research
Ethical Considerations for Pediatric Clinical Investigations
Additional Protections for Children Involved as Subjects in Research
Demystifying the IRB Process: An Interactive Conversation with QIP
Valdosta State University
Presentation transcript:

FDA Drug Advisory Committee Pediatric Ethics Subcommittee Gonadotropin Releasing Hormone Agonist Test in Disorders of Puberty CHARGE TO COMMITTEE Norman Fost MD MPH, Chair, PES Gaithersburg, Maryland, November 15, 2005

Purpose of the study Purpose: “To establish the diagnostic effectiveness of a (leuprolide) test and the norms for it. This will improve the differential diagnosis of the most common disorders of puberty so that we may provide more accurate and earlier treatment for these disorders.” Purpose: “To establish the diagnostic effectiveness of a (leuprolide) test and the norms for it. This will improve the differential diagnosis of the most common disorders of puberty so that we may provide more accurate and earlier treatment for these disorders.”

Use of normal healthy controls § Research not involving greater than minimal risk § Research not involving greater than minimal risk –IRB determined the risk was greater than minimal § Research involving greater than minimal risk but presenting the prospect of direct benefit to the individual subjects. § Research involving greater than minimal risk but presenting the prospect of direct benefit to the individual subjects. –IRB: No direct benefit § Research involving greater than minimal risk and no prospect of direct benefit to individual subjects, but likely to yield generalizable knowledge about the subject's disorder or condition. § Research involving greater than minimal risk and no prospect of direct benefit to individual subjects, but likely to yield generalizable knowledge about the subject's disorder or condition. –Normal children do not have a “condition” § Research not otherwise approvable which presents an opportunity to understand, prevent, or alleviate a serious problem affecting the health or welfare of children. § Research not otherwise approvable which presents an opportunity to understand, prevent, or alleviate a serious problem affecting the health or welfare of children.

Use of normal healthy controls § Research not involving greater than minimal risk § Research not involving greater than minimal risk –IRB determined the risk was greater than minimal § Research involving greater than minimal risk but presenting the prospect of direct benefit to the individual subjects. § Research involving greater than minimal risk and no prospect of direct benefit to individual subjects, but likely to yield generalizable knowledge about the subject's disorder or condition. – –Normal children do not have a “condition” – –Therefore, can not be approved under Section 406 § Research not otherwise approvable which presents an opportunity to understand, prevent, or alleviate a serious problem affecting the health or welfare of children. § Research not otherwise approvable which presents an opportunity to understand, prevent, or alleviate a serious problem affecting the health or welfare of children.

Options for the committee Can the use of normals be approved under Section 404? Can the use of normals be approved under Section 404? –§ Research not involving greater than minimal risk. –DHHS will conduct or fund research in which the IRB finds that no greater than minimal risk to children is presented, only if the IRB finds that adequate provisions are made for soliciting the assent of the children and the permission of their parents or guardians, as set forth in § §46.408

Minimal risk Minimal risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. Minimal risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.

Issues in determining minimal risk “Routine physical or psychological tests” interpreted variably by IRBs “Routine physical or psychological tests” interpreted variably by IRBs –Routine health supervision visit –Routine visit to a specialist Survey of IRB chairs Survey of IRB chairs

Section 407 (a) the IRB finds that the research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children; and (a) the IRB finds that the research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children; and (b) the Secretary, after consultation with a panel of experts in pertinent disciplines (for example: science, medicine, education, ethics, law) and following opportunity for public review and comment, has determined either: (b) the Secretary, after consultation with a panel of experts in pertinent disciplines (for example: science, medicine, education, ethics, law) and following opportunity for public review and comment, has determined either: (1) that the research in fact satisfies the conditions of §46.404, §46.405, or §46.406, as applicable, or (2) the following: (1) that the research in fact satisfies the conditions of §46.404, §46.405, or §46.406, as applicable, or (2) the following:§46.404§ §46.406§46.404§ § (i) the research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children; (i) the research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children; (ii) the research will be conducted in accordance with sound ethical principles; (ii) the research will be conducted in accordance with sound ethical principles; (iii) adequate provisions are made for soliciting the assent of children and the permission of their parents or guardians, as set forth in § (iii) adequate provisions are made for soliciting the assent of children and the permission of their parents or guardians, as set forth in § §46.408

Recommend approval under the IRB finds that the research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children.. the IRB finds that the research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children –Abnormal pubertal development is a serious problem –Is the availablity of a reliable diagnostic test a serious problem?

Vote: Issue #1 Does the proposal to study the response of normal children involve minimal risk? Does the proposal to study the response of normal children involve minimal risk? –Medical risks  Leuprolide  Procedures  Blood volume –Psychological risks of hospitalization and procedures

Vote: Issue #2 Is the need for improved diagnostic tests for diagnosis of problems of puberty a serious problem affecting the health of children? Is the need for improved diagnostic tests for diagnosis of problems of puberty a serious problem affecting the health of children?

Vote: Issue #3 Is the research designed in a way that “presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children.” Is the research designed in a way that “presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children.”